NAMS
NewAmsterdam Pharma Company N.V.
21.60$
+1.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | – | – | -5.3% | -88.8% | +0.0% | +56.8% | -80.1% | +71.3% | -72.7% | +74.5% | +62.7% | +1,177.4% | -56.1% | -76.7% | +542.9% | -98.2% | -90.8% | +9,400.0% | +21.7% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | +18.3% | – | – | – | – | +42.2% | -7.8% | +747.5% | – | – | |
| – | – | – | – | – | – | – | – | – | -5.3% | -88.8% | +0.0% | +56.8% | -80.1% | +71.3% | -72.7% | +72.6% | +64.4% | +1,177.4% | -56.1% | -76.7% | +542.9% | -98.2% | -107.8% | – | +45.7% | – | |
| – | +0.0% | +0.0% | +0.0% | +395.8% | +1.2% | +88.2% | +3.5% | +71.3% | -5.3% | +77.1% | +0.0% | +42.4% | -15.0% | +26.3% | -4.8% | +2.8% | -9.5% | -7.0% | -2.3% | +28.2% | -38.5% | +12.6% | +24.6% | -2.8% | +11.1% | – | |
| – | +0.0% | +0.0% | +0.0% | +131.8% | +1.2% | -77.3% | +646.0% | +249.3% | -5.3% | +2.2% | -13.1% | +54.0% | +51.0% | -14.9% | -13.9% | +37.9% | +24.2% | +16.6% | +158.2% | -23.4% | +0.4% | -10.1% | +11.6% | -14.3% | +14.7% | – | |
| – | – | – | – | +4,470.6% | -94.8% | +5,560.4% | +4.2% | +22.5% | -5.3% | +60.7% | +0.0% | +40.8% | -6.5% | +18.8% | -1.2% | +8.6% | -2.6% | -1.3% | +3.5% | +28.4% | -23.8% | +1.3% | +18.9% | -7.6% | +12.5% | – | |
| – | – | – | – | – | – | – | – | – | -5.3% | -199.9% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | -37.2% | +0.0% | +0.0% | +0.0% | – | – | – | – | +8.0% | +5,635.8% | -68.9% | +79.8% | -61.5% | +27.9% | +33.0% | +182.4% | – | – | – | – | – | – | – | |
| – | – | – | – | -13,508.0% | – | – | – | – | -5.3% | -233.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +0.0% | +5,950.0% | +0.0% | +0.0% | -85.1% | – | – | – | – | +211.3% | -199.9% | – | +111.4% | -11,574.1% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -13,508.0% | – | – | – | – | -5.3% | -233.2% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | -14,088.6% | – | – | – | – | -5.3% | -233.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.